Dantrolene, a ryanodine receptor stabilizer, is a candidate immunomodulator for treating rheumatic disease

T NawataT HondaH SakaiS TsujiM OtsukaH UchinoumiS KobayashiT YamamotoM AsagiriM Yano1 Department of Medicine and Clinical Science,Yamaguchi University Graduate School of Medicine,Ube,Japan2 Department of Pharmacology,Yamaguchi University Graduate School of Medicine,Ube,Japan3 Faculty of Health Sciences,Yamaguchi University Graduate School of Medicine,Ube,Japan
DOI: https://doi.org/10.1080/03009742.2023.2297519
2024-02-01
Scandinavian Journal of Rheumatology
Abstract:Dantrolene, a ryanodine receptor stabilizer, is a potential therapeutic drug against various diseases such as ventricular tachycardia, hepatic steatosis, and Alzheimer's disease ( Citation 1–3 ). It may also serve as a therapeutic agent against autoimmune diseases ( Citation 4 , Citation 5 ). We previously reported that oral dantrolene administration significantly reduced serum anti-type II collagen (CII) immunoglobulin G (IgG) levels in mice with collagen-induced arthritis (CIA), consequently preventing CIA ( Citation 4 ). These results highlight the potential for dantrolene as an anti-rheumatic drug. Herein, we further explore whether dantrolene acts as an immunosuppressant or immunomodulator.
rheumatology
What problem does this paper attempt to address?